Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports
Erschienen in: Current Bladder Dysfunction Reports 3/2015

01.09.2015 | Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Update in Diagnosis and Treatment of Chronic Pelvic Pain Syndromes

verfasst von: Nima Shah, Natasha Ginzburg, Darlene Morrissey, Kristene Whitmore

Erschienen in: Current Bladder Dysfunction Reports | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

The diagnosis and treatment of chronic pelvic pain have shifted from organ-specific to multifactorial, multidisciplinary, and individualized approach. While many organizations have had diverse outlooks on classification and treatment plans, new research has identified varied clinical phenotypes and updated classification systems. These phenotypes are based on pain, gender, symptomatology, and comorbid pain syndromes. These new classification systems allow a multimodal therapeutic approach and evaluation of patients. Multidisciplinary care, including urology, gynecology, gastroenterology, neurology, psychology, physiotherapy, and pain medicine, is also further recognized for adequate management of patients with chronic pelvic pain because of its variable etiology. The purpose of this review is to emphasize these changes and discuss management strategies.
Literatur
1.
2.
Hanno P et al. Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol Urodyn. 2010;29(1):191–8.CrossRefPubMed
3.••
Engeler DS et al. The 2013 EAU guidelines on chronic pelvic pain: is management of chronic pelvic pain a habit, a philosophy, or a science? 10 years of development. Eur Urol. 2013;64(3):431–9. Discussion of updated EAU guidelines on chronic pelvic pain, as well as description of UPOINT phenotyping classification symptom.CrossRefPubMed
4.
5.
Shoskes DA et al. Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromes. Prostate Cancer Prostatic Dis. 2009;12(2):177–83.CrossRefPubMed
6.
Nickel JC, Shoskes DA, Irvine-Bird K. Clinical phenotyping of women with interstitial cystitis/painful bladder syndrome: a key to classification and potentially improved management. J Urol. 2009;182(1):155–60.CrossRefPubMed
7.
Konkle KS et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012;187(2):508–12.PubMedCentralCrossRefPubMed
8.
Gamper M, et al. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J Urol. 2015;193(6):1994–2000.
9.
Russell AL. Glycoaminoglycan (GAG) deficiency in protective barrier as an underlying, primary cause of ulcerative colitis, Crohn’s disease, interstitial cystitis and possibly Reiter’s syndrome. Med Hypotheses. 1999;52(4):297–301.CrossRefPubMed
10.
Logadottir Y et al. Inflammation characteristics in bladder pain syndrome ESSIC type 3C/classic interstitial cystitis. Int J Urol. 2014;21 Suppl 1:75–8.CrossRefPubMed
11.
van de Merwe JP et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol. 2008;53(1):60–7.CrossRefPubMed
12.
Humphrey L et al. The bladder pain/interstitial cystitis symptom score: development, validation, and identification of a cut score. Eur Urol. 2012;61(2):271–9.CrossRefPubMed
13.
Hanno PM et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–70.CrossRefPubMed
14.
Kuo YC, Kuo HC. The urodynamic characteristics and prognostic factors of patients with interstitial cystitis/bladder pain syndrome. Int J Clin Pract. 2013;67(9):863–9.CrossRefPubMed
15.••
Nickel JC, Tripp DA, G. International Interstitial Cystitis Study. Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. J Urol. 2015;193(1):138–44. This study identifies two major pain phenotypes in patients with IC/BPS and its association with somatic pain syndromes.CrossRefPubMed
16.
Nickel JC et al. Interstitial cystitis/painful bladder syndrome and associated medical conditions with an emphasis on irritable bowel syndrome, fibromyalgia and chronic fatigue syndrome. J Urol. 2010;184(4):1358–63.CrossRefPubMed
17.••
Krieger JN, et al. Relationship between chronic nonurological associated somatic syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evaluation of the MAPP study. J Urol. 2014;193(4):1254–62. Baseline evaluation of the MAPP study which evaluates relationship between non-urological associated somatic syndromes and urologic chronic pelvic pain syndromes. Those with associated non-urological somatic syndromes had more severe urological symptoms and more frequent depression and anxiety.
18.
Bogart LM et al. Prevalence and correlates of sexual dysfunction among women with bladder pain syndrome/interstitial cystitis. Urology. 2011;77(3):576–80.PubMedCentralCrossRefPubMed
19.
Kartha GK, Kerr H, Shoskes DA. Clinical phenotyping of urologic pain patients. Curr Opin Urol. 2013;23(6):560–4.CrossRefPubMed
20.•
Hanno PM, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA Guideline Amendment. J Urol. 2015;193(5):1545–53. Amendment to the 2011 AUA Guidelines for diagnosis and treatment of IC/BPS.
21.
Nickel JC et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):1–11.CrossRef
22.
FitzGerald MP et al. Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. J Urol. 2012;187(6):2113–8.PubMedCentralCrossRefPubMed
23.
Pinto R et al. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J Urol. 2013;189(2):548–53.CrossRefPubMed
24.
Peters KM, Konstandt D. Sacral neuromodulation decreases narcotic requirements in refractory interstitial cystitis. BJU. 2004;93:777–9.CrossRef
25.
Wein A. Short-term results of bilateral S2-S4 sacral neuromodulation for the treatment of refractory interstitial cystitis, painful bladder syndrome, and chronic pelvic pain editorial comment. J Urol. 2010;183(2):570.CrossRef
26.
Whitmore K. Complementary and alternative therapies as treatment approaches for interstitial cystitis. Rev Urol. 2002;4(1):S28–35.PubMedCentralPubMed
27.
O'Hare 3rd PG et al. Interstitial cystitis patients’ use and rating of complementary and alternative medicine therapies. Int Urogynecol J. 2013;24(6):977–82.CrossRefPubMed
28.
Chuang YC et al. Increased risks of healthcare-seeking behaviors of anxiety, depression and insomnia among patients with bladder pain syndrome/interstitial cystitis: a nationwide population-based study. Int Urol Nephrol. 2015;47(2):275–81.CrossRefPubMed
29.
Krsmanovic A et al. Psychosocial mechanisms of the pain and quality of life relationship for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Can Urol Assoc J. 2014;8(11-12):403–8.PubMedCentralCrossRefPubMed
30.
Nickel JC et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(1):175–9.CrossRefPubMed
31.
Krieger J, Nyberg Jr L, Nickel C. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(2):236–7.CrossRefPubMed
32.
Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M, et al. Management of chronic prostatitis/chronic pelvic pain syndrome. JAMA. 2011;305(1):78–86.CrossRefPubMed
33.
Rees J, Abrahams M, Doble A, Cooper A. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU Int. 2015(February 24). doi:10.​1111/​bju.​13101 .
34.•
Shoskes DA, Nickel JC. Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the UPOINT system. World J Urol. 2013;31(4):755–60. This study describes the UPOINT classification system within the realms of chronic prostatitis/chronic pelvic pain syndrome.CrossRefPubMed
35.
Wagenlehner FM et al. National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2013;63(5):953–9.CrossRefPubMed
36.
Nickel JC et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? J Urol. 2006;176(1):119–24.CrossRefPubMed
37.
Galley HF et al. Effect of ciprofloxacin on the accumulation of interleukin-6, interleukin-8, and nitrite from a human endothelial cell model of sepsis. Crit Care Med. 1997;25(8):1392–5.CrossRefPubMed
38.
Katsuno G et al. The immunosuppressive effects of ciprofloxacin during human mixed lymphocyte reaction. Clin Immunol. 2006;119(1):110–9.CrossRefPubMed
39.
Nickel JC et al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol. 2003;169(4):1401–5.CrossRefPubMed
40.
Zhao WP et al. Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA). Braz J Med Biol Res. 2009;42(10):963–7.CrossRefPubMed
41.
Kaplan SA, Volpe MA, Te AE. A prospective, 1-year trial using saw palmetto versus finasteride in the treatment of category III prostatitis/chronic pelvic pain syndrome. J Urol. 2004;171(1):284–8.CrossRefPubMed
42.
Leskinen M, Lukkarinen O, Marttila T. Effects of finasteride in patients with inflammatory chronic pelvic pain syndrome: a double-blind, placebo-controlled, pilot study. Urology. 1999;53(3):502–5.CrossRefPubMed
43.
Nickel JC et al. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol. 2011;186(4):1313–8.CrossRefPubMed
44.
Grimsley SJ, Khan MH, Jones GE. Mechanism of phosphodiesterase 5 inhibitor relief of prostatitis symptoms. Med Hypotheses. 2007;69(1):25–6.CrossRefPubMed
45.
Herati AS, Moldwin RM. Alternative therapies in the management of chronic prostatitis/chronic pelvic pain syndrome. World J Urol. 2013;31(4):761–6.CrossRefPubMed
46.
Lee SH, Lee BC. Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. Urology. 2009;73(5):1036–41.CrossRefPubMed
47.
Posadzki P et al. Acupuncture for chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a systematic review. J Androl. 2012;33(1):15–21.CrossRefPubMed
48.
Khorasani B et al. Transabdominal ultrasound measurement of pelvic floor muscle mobility in men with and without chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80(3):673–7.CrossRefPubMed
49.
Clemens JQ et al. Biofeedback, pelvic floor re-education, and bladder training for male chronic pelvic pain syndrome. Urology. 2000;56(6):951–5.CrossRefPubMed
50.
Cornel EB et al. The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III. Eur Urol. 2005;47(5):607–11.CrossRefPubMed
51.
Fitzgerald MP et al. Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol. 2013;189(1 Suppl):S75–85.CrossRefPubMed
52.
Riegel B et al. Assessing psychological factors, social aspects and psychiatric co-morbidity associated with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men—a systematic review. J Psychosom Res. 2014;77(5):333–50.CrossRefPubMed
53.•
Nickel JC, et al. Search for microorganisms in men with urologic chronic pelvic pain syndrome: a culture-independent analysis in the MAPP Research Network. J Urol. 2015;194(1):127–35. This article determined feasibility of a randomized clinical trial of manual therapy techniques and showed excellent therapist adherence and high global response assessment rate for the myofascial physical therapy group.
54.
Quick ML et al. CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am J Physiol Regul Integr Comp Physiol. 2012;303(6):R580–9.PubMedCentralCrossRefPubMed
55.
Wong L et al. Experimental autoimmune prostatitis induces microglial activation in the spinal cord. Prostate. 2015;75(1):50–9.CrossRefPubMed
56.
Tu FF, As-Sanie S, Steege JF. Prevalence of pelvic musculoskeletal disorders in a female chronic pelvic pain clinic. J Reprod Med. 2006;51(3):185–9.PubMed
57.
Bassaly R et al. Myofascial pain and pelvic floor dysfunction in patients with interstitial cystitis. Int Urogynecol J. 2011;22(4):413–8.CrossRefPubMed
58.
Bennett R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2007;21(3):427–45.CrossRefPubMed
59.
Alvarez DJ, Rockwell PG. Trigger points: diagnosis and management. Am Fam Physician. 2002;65(4):653–60.PubMed
60.
Gyang A, Hartman M, Lamvu G. Musculoskeletal causes of chronic pelvic pain: what a gynecologist should know. Obstet Gynecol. 2013;121(3):645–50.CrossRefPubMed
61.
Prendergast SA, Weiss JM. Screening for musculoskeletal causes of pelvic pain. Clin Obstet Gynecol. 2003;46(4):773–82.CrossRefPubMed
62.
Cummings M, Baldry P. Regional myofascial pain: diagnosis and management. Best Pract Res Clin Rheumatol. 2007;21(2):367–87.CrossRefPubMed
63.
Curatolo M, Arendt-Nielsen L, Petersen-Felix S. Evidence, mechanisms, and clinical implications of central hypersensitivity in chronic pain after whiplash injury. Clin J Pain. 2004;20(6):469–76.CrossRefPubMed
64.
FitzGerald MP, Kotarinos R. Rehabilitation of the short pelvic floor. I: background and patient evaluation. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14(4):261–8.CrossRefPubMed
65.
Simons DG, Travell J. Myofascial trigger points, a possible explanation. Pain. 1981;10(1):106–9.CrossRefPubMed
66.
McPartland JM. Travell trigger points—molecular and osteopathic perspectives. J Am Osteopath Assoc. 2004;104(6):244–9.PubMed
67.
Dhingra C et al. Urogynecological causes of pain and the effect of pain on sexual function in women. Female Pelvic Med Reconstr Surg. 2012;18(5):259–67.CrossRefPubMed
68.
Crisp CC et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J. 2013;24(11):1915–23.CrossRefPubMed
69.
70.
Abbott JA et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108(4):915–23.CrossRefPubMed
71.
Thomson AJ et al. The use of botulinum toxin type A (BOTOX) as treatment for intractable chronic pelvic pain associated with spasm of the levator ani muscles. BJOG. 2005;112(2):247–9.CrossRefPubMed
72.
Moyal-Barracco M, Lynch PJ. 2003 ISSVD terminology and classification of vulvodynia: a historical perspective. J Reprod Med. 2004;49(10):772–7.PubMed
73.
Ventolini G. Vulvar pain: anatomic and recent pathophysiologic considerations. Clin Anat. 2013;26(1):130–3.CrossRefPubMed
74.
75.
Leo RJ. A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med. 2013;10(8):2000–8.CrossRefPubMed
76.
77.•
Hampson JP et al. Augmented central pain processing in vulvodynia. J Pain. 2013;14(6):579–89. This article describes central pain processing in patients with vulvodynia via MRI.PubMedCentralCrossRefPubMed
78.
79.
Ventolini G et al. Vulvodynia and fungal association: a preliminary report. Med Hypotheses. 2013;81(2):228–30.CrossRefPubMed
80.
81.
Bouchard C. Use of oral contraceptive pills and vulvar vestibulitis: a case-control study. Am J Epidemiol. 2002;156(3):254–61.CrossRefPubMed
82.
Pagano R, Wong S. Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. J Lower Genital Tract Dis. 2012;16(4):394–7.CrossRef
83.
Zolnoun D. Overnight 5% lidocaine ointment for treatment of vulvar vestibulitis. Obstet Gynecol. 2003;102(1):84–7.CrossRefPubMed
84.
Steinberg AC et al. Capsaicin for the treatment of vulvar vestibulitis. Am J Obstet Gynecol. 2005;192(5):1549–53.CrossRefPubMed
85.
McDonald JS, Rapkin AJ. Multilevel local anesthetic nerve blockade for the treatment of generalized vulvodynia: a pilot study. J Sex Med. 2012;9(11):2919–26.CrossRefPubMed
86.
Fariello JY, Whitmore K. Sacral neuromodulation stimulation for IC/PBS, chronic pelvic pain, and sexual dysfunction. Int Urogynecol J. 2010;21(12):1553–8.CrossRefPubMed
87.
Ramsay LB, Wright Jr J, Fischer JR. Sacral neuromodulation in the treatment of vulvar vestibulitis syndrome. Obstet Gynecol. 2009;114:487–9.CrossRefPubMed
88.
De Andres J et al. Peripheral subcutaneous vulvar stimulation in the management of severe and refractory vulvodynia. Obstet Gynecol. 2013;121(2):495–8.PubMed
89.
Schlaeger JM, et al. Acupuncture for the treatment of vulvodynia: a randomized wait-list controlled pilot study. J Sex Med. 2015;12(4):1019–27.
90.
Heddini U et al. Provoked vestibulodynia—medical factors and comorbidity associated with treatment outcome. J Sex Med. 2012;9(5):1400–6.CrossRefPubMed
91.
Liu B et al. Adding a sexual dysfunction domain to UPOINT system improves association with symptoms in women with interstitial cystitis and bladder pain syndrome. Urology. 2014;84(6):1308–13.CrossRefPubMed
Metadaten
Titel
Update in Diagnosis and Treatment of Chronic Pelvic Pain Syndromes
verfasst von
Nima Shah
Natasha Ginzburg
Darlene Morrissey
Kristene Whitmore
Publikationsdatum
01.09.2015
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports / Ausgabe 3/2015
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-015-0302-y

Weitere Artikel der Ausgabe 3/2015

Current Bladder Dysfunction Reports 3/2015 Zur Ausgabe

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Diagnosis and Management of Urachal Anomalies in Children

Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Primary Bladder Neck Obstruction in Men and Women: an Update on Diagnosis and Management

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Bladder Tissue Engineering for Pediatric Urology

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Evaluation and Treatment Urosepsis

Post-Prostatectomy and Acquired Voiding Dysfunction (V Tse, Section Editor)

Pelvic Irradiation and Its Effects on the Lower Urinary Tract: a Literature Review

Pediatric Bladder Dysfunction (SJ Hodges, Section Editor)

Posterior Urethral Valves

Neu im Fachgebiet Urologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise